The aim of the present study was to investigate changes in short-term visual acuity and foveal thickness after single-dose intravitreal bevacizumab treatments for macular edema secondary to central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).
INTRODUCTION
In cases of branch retinal vein occlusion (BRVO), and central retinal vein occlusion (CRVO), the most predominant cause of visual impairment is macular edema. Laser photocoagulation and intravitreal drug applications have been investigated in the treatment of macular edema associated with retinal vein occlusion (RVO).
In both BRVO and CRVO, the intraocular level of vascular endothelial growth factor (VEGF) increases. [1] One study reported that CRVO treated with intravitreal bevacizumab injection administered every 6 weeks for 6 months resulted in a decrease in macular edema and an increase in the level of visual acuity. [2] Based on these results, the effectiveness of intravitreal bevacizumab injections for macular edema that developed as an outcome of BRVO was studied, and it was used as a treatment alternative. [3] The effectiveness of other anti-VEGFs (ranibizumab and afflibercept) in the treatment of macular edema as a result of both CRVO and BRVO has also been demonstrated in many studies. [4] [5] [6] [7] This study of patients with macular edema was an evaluation of changes in visual acuity and foveal thickness after treatment with single-dose intravitreal bevacizumab injections at monthly intervals for a period of 3 months and an assessment of complications arising from the therapy.
MATERIAL AND METHODS
A total of 28 eyes of 28 patients who presented at the clinic between January 2012 and February 2015 and who received intravitreal bevacizumab (Avastin; Genentech Inc., South San Francisco, CA, USA) injections for the treatment of macular edema that developed as an outcome of BRVO or CRVO were retrospectively reviewed. Optical coherence tomography (OCT) (spectral domain OCT/SLO; OTI-OPKO Health Inc., Miami, FL, USA) measurements taken before treatment and 1, 2, and 3 months after injections to eyes with BRVO or CRVO with were included in the research.
Other inclusion criteria were detection of macular edema secondary to BRVO or CRVO during ophthalmoscopic evaluation, foveal thickness >250 µm measured during OCT analysis, initial visual acuity based on Early Treatment Diabetic Retinopathy Study (ETDRS) chart score (Snellen equivalent) of ≤75 (20/32). Patients with another organic eye disease that might induce a decrease in visual acuity were not included in the study. The patients were informed about possible complications of intraocular injection, and provided written, informed consent. A comprehensive ophthalmologic evaluation was performed before administering an injection, and at first, second, and third months, after the injection was given. The best corrected visual acuity was evaluated using the ETDRS scale. The anterior segment was examined using slit lamp biomicroscopy, and fundus examination was performed with indirect ophthalmoscopy. Intraocular pressure was measured and recorded with a Goldmann applanation tonometer. The presence of foveal ischemia before injection was evaluated using fundus fluorescein angiography. Foveal thickness was measured using spectral domain OCT. The thickness of 1 mm of central fovea was determined using the fast retinal map program each month for a period of 3 months.
Intravitreal bevacizumab was injected into 28 eyes of 28 patients with RVO and macular edema observed on first examination. Injections were performed in the operating room in compliance with sepsis-antisepsis protocol. After achievement of topical anesthesia with 0.5% proparacaine, the eye was irrigated with 5% povidone iodine. A 30-G needle was inserted through the pars plana 3.5 to 4.0 mm from the limbus, avoiding the lens, on the horizontal meridian and with consideration for the axial length of the eye. The injection of 1.25 mg/0.05 mL bevacizumab was then delivered into the central vitreus. Ciprofloxacin eye drops were prescribed for use 5 times a day for 7 days after the injection for prophylactic purposes.
Sociodemographic and disease-related data of the patients are provided in Table 1 . The cases were divided into 2 groups: macular edema secondary to BRVO and to CRVO. In the BRVO group, 18 eyes of 18 patients were included. These patients had either superior temporal (n=12; 66.6%) or inferior temporal vein (n=6; 33.3%) occlusion. There were 10 eyes of 10 patients in the CRVO group. Among all 28 cases, the concomitant diseases of hypertension (n=15; 53.57%), bleeding diathesis (n=4; 14.28%), type 2 diabetes mellitus (n=3; 10.71%), heart failure (n=2; 7.14%), hypothyroidism (n=1; 3.57%), hypercholesterolemia (n=1; 3.57%), autosomal dominant drusen ((n=1; 3.57%), and macular degeneration secondary to dry eye (n=1; 3.57 %) were detected. The mean time interval between the onset of the disease and the first injection was 19.39±25.41 days (median: 10 days).
The following parameters were investigated: the best corrected visual acuity, changes in foveal thickness determined using spectral domain OCT, and complications related to the intravitreal injections. SPSS Statistics for Windows, Version 17.0 (SPSS Inc., Chicago, IL, USA) was used for the statistical evaluation of findings. The data were analyzed using paired samples t-test, and p<0.05 was accepted as the level of statistical significance for intergroup differences.
RESULTS
The mean age of the 28 patients (female: n=15; 53.57% and male: n=13; 46.44%) was 58.60±8.94 years (range: 43-80 years). The mean time interval from disease onset to injection was 19.39±25.41 days (median: 10 days).
Independent samples t-test analysis of the demographic data did not reveal a statistically significant difference between the 2 groups based on age (p=0.96), gender (p=0.31), time interval from disease onset to injection (p=0.83), or baseline foveal thickness (p=0.91).
The mean foveal thickness measured with OCT before and after monthly intravitreal bevacizumab injections is provided in Table 2 . In the BRVO group, the mean (±SD) foveal thickness was 415.26±70.14 μm before treatment, and 270.55±43.52 μm, 283.88±43.20 μm, and 322.77±52.97 μm at 1, 2, and 3 months, respectively ( Table 2) . When compared with the baseline measurement, the decrease in foveal thickness at first and second months was substantial, and statistically significant (p<0.001). The smaller decrease in foveal thickness detected at third month was also statistically significant (p<0.05).
In the CRVO group, the mean initial foveal thickness was 425.71±66.08 μm, and it was 361.15±84.43 μm, 378.50±71.34 μm, and 388.63±88.38 μm at 1, 2, and 3 months after beginning treatment, respectively ( Table 2) . When compared with the pre-injection value, the decrease in foveal thickness at the first month was statistically significant (p<0.05), while subsequent decreases in foveal thickness were not found to be statistically significant (p>0.05).
The mean ETDRS letter chart scores (Snellen score equivalent) before, and 1,2, and 3 months after injections are shown in Table 3 .
In the group with BRVO, the mean ETDRS score was 63.61±19.42 (20/100) before treatment, and 83.05±10.15 (20/40), 81.11±12.42 (20/50), and 77.77±13.25 (20/60) at postinjection first, second, and third months, respectively ( Table 3 ). Based on the preinjection ETDRS score, the increase in visual acuity at months 1 and 2 was considerable, and statistically significant (p<0.001). A smaller, but still statistically significant increase in visual acuity was detected at month 3 (p<0.05).
In the CRVO group, the preliminary mean ETDRS score was 33.14±6.09 (20/400), and mean score was 45.14±16.64 (20/250), 41.15±15.03 (20/320), and 26.47±10.35 (20/500) at months 1, 2, and 3, respectively (Table 3 ). When compared with the preinjection ETDRS score, the increase in visual acuity seen in subsequent months was not statistically significant (p>0.05).
During the follow-up period, no systemic side effects of bevacizumab were observed, and no ophthalmological complications were encountered. 
DISCUSSION
RVO is a frequently seen disease of the retinal vasculature, second only to diabetic retinopathy. Though RVO has been defined as a single disease group, CRVO and BRVO differ in pathogenesis and treatment response. Macular edema is the predominant cause of visual impairment in both CRVO and BRVO. In RVO, interruption of blood circulation and a disruption of the blood-retina barrier lead to plasma exudation and subsequent macular edema. Treatment modalities targeting both pathogenetic factors and the formation of edema have been investigated. Although hemodilution therapy has been proposed as a treatment approach that would restore retinal blood flow to normal level, successful outcomes have not yet been achieved. [8] Laser therapy and various intravitreal injections have also been studied.
Since macular edema can lead to irreversible photoreceptor damage, which may develop within just 3 months, it should be treated at an early stage of the disease. [9] In our study, we administered intravitreal single-dose bevacizumab injections over the first 3 months of disease in order to prevent photoreceptor injury, to assess shortterm progression of venous occlusion in both groups, and to evaluate the need for additional early-stage treatment, such as laser photocoagulation.
Prognosis of visual acuity outcome is largely dependent on initial acuity. In cases with non-ischemic CRVO, without treatment, fewer than 10% of patients will recover normal visual acuity. [10] The Central Vein Occlusion Study (CVOS) group demonstrated that baseline visual acuity is an important marker in the prediction of final degree of visual acuity, and is associated with presence of retinal perfusion. [11] For example it has been demonstrated that 65% of the patients who had baseline visual acuity of ≥20/40 preserved this good level of visual acuity, and 80% of the cases with visual acuity of ≤20/200 retained poor visual acuity.
The outcomes of the CVOS study group also indicated that follow-up intervals should be determined based on initial visual acuity and the presence of ischemia. [7, 11] The CVOS study and others have demonstrated that the use of new anti-VEGF agents and intravitreal steroid applications has achieved improved treatment results. [1, 3, 7, [11] [12] [13] Focal laser therapy for macular edema is not recommended in CRVO in the CVOS study, as the grid-like laser treatment applied to the macular area did not provide a positive effect on final visual acuity. [14] In our study, the therapeutic effects of intravitreal 1.25 mg bevacizumab injection on visual acuity and foveal thickness in 28 cases with macular edema that developed as an outcome of BRVO or CRVO were investigated. In the BRVO group, when compared with preinjection values, a statistically significant decrease in foveal thickness was seen at 1 and 2 months after initial injection (p<0.01) while at third month, a smaller, but still statistically significant, decrease was observed (p<0.05). In the CRVO group, when compared with preinjection measurements, a statistically significant decrease in foveal thickness was seen at the first month (p<0.05). Decreases at second and third months were not statistically significant (p>0.05). In the BRVO group, an increase in ETDRS score was determined at months 1 and 2 after treatment, which were statistically significant relative to preinjection score (p<0.01), while smaller statistically significant increase (p<0.05) was recorded at the third month. In the CRVO group, relative to preinjection value, the increase in ETDRS score was not statistically significant (p>0.05) at any interval. Single-dose intravitreal bevacizumab injections decreased macular edema in cases with BRVO for three consecutive months, retinal thickness was maintained within normal limits, and statistically significant increases in visual acuity were observed. In CRVO patients, a statistically significant decrease in macular edema was observed at 1 month after injection; however, intravitreal bevacizumab gradually lost its therapeutic effect beginning at month 2, and at final post-treatment evaluation, no statistically significant increase in visual acuity was achieved.
Stahl et al. suggested that the appropriate anatomical and Table 3 . Mean ETDRS visual acuity score before injection and 1, 2, and 3 months after injection
Branch retinal vein occlusion (n=18) Central retinal vein occlusion (n=10)
functional vascularization process may take a very long time in cases of RVO, and that circulation can be maintained with collateral vascular vessels. Therefore, they asserted that bevacizumab treatment should be continued until appropriate retinal circulation was achieved. [15] Based on our results, however, we would suggest that, particularly in cases with CRVO, single-dose bevacizumab monotherapy may fail to have adequate therapeutic effect.
We detected no ophthalmological complications related to intravitreal bevacizumab injections. A lack of any change in electrophysiological values after intravitreal bevacizumab injections in cases of RVO has been demonstrated. [16] In that study, single-dose intravitreal bevacizumab injections were administered for 9 CRVO and 12 BRVO eyes with macular edema, and the patients were followed up for 12 weeks. No sign of ocular toxicity was observed at the conclusion of the research. The present study was designed to evaluate the early course of disease in these 2 groups, and to assess the need for recurrent injections at an early stage.
One of the limitations of our study is the small number of participants. In addition, it was not prospective in nature, and there was no control group. Furthermore, bevacizumab is not licensed for intravitreal use.
A statistically significant increase in visual acuity seen 1 month after intravitreal bevacizumab injection was maintained through the third month in the BRVO group; however, a similar effect was not seen in the CRVO group. Though a statistically significant decrease in foveal thickness was obtained in the CRVO group when compared with pre-injection values, which indicated achievement of some functional and anatomical improvement, the same degree of improvement as in the BRVO group was not observed, suggesting the presence of greater damage in the CRVO group. In conclusion, treatment of macular edema that had developed as a result of RVO using intravitreal bevacizumab injections in the early phase had successful results. However, we think that a full evaluation of results on this topic requires larger, prospective studies.
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